Meeting
2016 ASCO Annual Meeting
Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.
Authors
Olivier L. Chinot
Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France
Olivier L. Chinot , Josep Garcia , Sylvie Romain , Cedric Revil , Timothy Cloughesy , Warren P. Mason , Ryo Nishikawa , Roger Henriksson , Frank Saran , Antoine F. Carpentier , Khe Hoang-Xuan , Petr Kavan , Dana Cernea , Alba Ariela Brandes , Yannick Kerloeguen , Christoph Mancao , L'Houcine Ouafik , Lauren E. Abrey , Wolfgang Wick , Emeline Tabouret
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00943826
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2020)
DOI
10.1200/JCO.2016.34.15_suppl.2020
Abstract #
2020
Poster Bd #
209
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Donna Molaie
Poster
2016 ASCO Annual Meeting
Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).
First Author: Martha Nowosielski
Poster
2014 ASCO Annual Meeting
Plasma levels and tumor tissue RNA of MMP2 and MMP9 exhibit similar distribution in newly diagnosed and recurrent glioblastoma (GB).
First Author: Emeline Tabouret
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger